Abstract
Elderly patients (pts) are often considered ineligible for effective cancer (Ca) treatments (TXS) because of reported inferior survival (S) compared to (vs) ideal trial pts and concerns due to high risk of severe adverse events (AEs). Pts with gastrointestinal (G)I cancer are often un- or undertreated even when the goals are a potential cure. Development series 2000 -2019 found that palliative regimens GFLIO which exploit 3 simultaneous 1/2-1/3 dosage drug interactions, in preference to standard dosages, are effective and safe (Anticancer Research 2016, 2018 ACR).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
